Bioverativ Stock Price, News & Analysis (NASDAQ:BIVV)

$53.21 -0.26 (-0.49 %)
(As of 12/17/2017 10:29 AM ET)
Previous Close$53.21
Today's Range$52.67 - $53.75
52-Week Range$40.00 - $64.41
Volume3.72 million shs
Average Volume1.26 million shs
Market Capitalization$5.76 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Bioverativ (NASDAQ:BIVV)

Bioverativ logoBioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive BIVV News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIVV
CUSIPN/A
Phone781-663-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.01%
Quick Ratio1.90%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio21.72
P/E Growth1.55

Sales & Book Value

Annual Sales$887.40 million
Price / Sales6.49
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net Income$439.60 million
Net Margins40.44%
Return on Equity69.03%
Return on Assets40.94%

Miscellaneous

Employees350
Outstanding Shares108,200,000

Bioverativ (NASDAQ:BIVV) Frequently Asked Questions

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

How were Bioverativ's earnings last quarter?

Bioverativ Inc (NASDAQ:BIVV) announced its quarterly earnings data on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.25. The biotechnology company had revenue of $291.60 million for the quarter, compared to analysts' expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business's quarterly revenue was up 27.2% on a year-over-year basis. View Bioverativ's Earnings History.

When will Bioverativ make its next earnings announcement?

Bioverativ is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Bioverativ.

Where is Bioverativ's stock going? Where will Bioverativ's stock price be in 2017?

16 analysts have issued 12 month target prices for Bioverativ's shares. Their forecasts range from $47.00 to $80.00. On average, they anticipate Bioverativ's share price to reach $60.36 in the next twelve months. View Analyst Ratings for Bioverativ.

What are Wall Street analysts saying about Bioverativ stock?

Here are some recent quotes from research analysts about Bioverativ stock:

  • 1. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (11/1/2017)
  • 2. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)
  • 3. Stifel Nicolaus analysts commented, "On Friday Bioverativ reported FY16 earnings that included revenue of $887.4 million and net income of $439.6 million. As Biogen reported FY16 numbers that included the Eloctate and Alprolix sales, revenue was in-line with our expectations while expenses were slightly lower in addition to a one-time income tax benefit of $147.7 million. Based on this slightly better than expected expense line, we are raising our target price from $54 to $57. Key questions remain concerning the future research and development spend - which seems slightly high for the collection of clinical trials and selling, general & administrative expenses that decreased Y/Y. We note our change in target price is derived principally from less 2016 SG&A spend than expected ' leaving room for additional PT increase if the R&D line decreases as well. One of the features we like about Bioverativ is the pipeline that seems both interesting and relatively reduced risk and the company anticipates launching a Phase I trial of BIVV001 during 2H17." (3/27/2017)
  • 4. Credit Suisse Group AG analysts commented, "We are initiating coverage of Bioverativ with an Underperform rating and $45 target price. We think the company's current valuation does not reflect enough risk from new long-acting therapies and novel pipeline competitors: Bioverativ is a pure-play hemophilia company that was spun off from Biogen in early 2017 with commercial assets (Eloctate and Alprolix). We think over the next few years that novel products will emerge from competitors that will pressure sales for its products. Although BIVV has pipeline assets similar to competitors, we think that there is a meaningful difference in development timelines. Competitive datasets over the year could drive volatility in BIVV shares since we don't expect major pipeline catalysts from BIVV this year. If we assume no market share loss from competitors, our FV is $54/share which is limited upside from current levels. Significant upside to the stock is driven by greater confidence in the pipeline which still remains early in our opinion." (3/16/2017)

Who are some of Bioverativ's key competitors?

Who are Bioverativ's key executives?

Bioverativ's management team includes the folowing people:

  • Brian S. Posner, Independent Chairman of the Board (Age 55)
  • John G. Cox, Chief Executive Officer, Director (Age 54)
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
  • Richard Brudnick, Executive Vice President - Business Development (Age 60)
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Louis J. Paglia, Independent Director (Age 59)

Who owns Bioverativ stock?

Bioverativ's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wells Fargo & Company MN (2.02%), Woodford Investment Management Ltd (1.81%), Jackson Square Partners LLC (1.61%), Old Mutual Global Investors UK Ltd. (1.57%), ValueAct Holdings L.P. (1.17%) and Bank of New York Mellon Corp (1.15%). Company insiders that own Bioverativ stock include Alexander J Denner, Brian S Posner, Diantha Duvall and Louis J Paglia. View Institutional Ownership Trends for Bioverativ.

Who bought Bioverativ stock? Who is buying Bioverativ stock?

Bioverativ's stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Woodford Investment Management Ltd, Jackson Square Partners LLC, Old Mutual Global Investors UK Ltd., ValueAct Holdings L.P., Bank of New York Mellon Corp, Sarissa Capital Management LP and Janus Henderson Group PLC. Company insiders that have bought Bioverativ stock in the last two years include Alexander J Denner, Brian S Posner and Louis J Paglia. View Insider Buying and Selling for Bioverativ.

How do I buy Bioverativ stock?

Shares of Bioverativ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioverativ's stock price today?

One share of Bioverativ stock can currently be purchased for approximately $53.21.

How big of a company is Bioverativ?

Bioverativ has a market capitalization of $5.76 billion and generates $887.40 million in revenue each year. Bioverativ employs 350 workers across the globe.

How can I contact Bioverativ?

Bioverativ's mailing address is 225 2ND AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-663-4400 or via email at [email protected]


MarketBeat Community Rating for Bioverativ (BIVV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioverativ (NASDAQ:BIVV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.442.442.382.45
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $60.36$61.21$59.43$54.55
Price Target Upside: 18.91% upside1.65% upside5.30% upside3.90% upside

Bioverativ (NASDAQ:BIVV) Consensus Price Target History

Price Target History for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ:BIVV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017Deutsche BankSet Price TargetHold$53.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$71.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingUnderweight$45.00 -> $47.00N/AView Rating Details
9/20/2017ArgusUpgradeHold -> Buy$64.00MediumView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform -> Sector Perform$59.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$58.00HighView Rating Details
8/9/2017Jefferies GroupReiterated RatingBuy$67.00 -> $70.00LowView Rating Details
8/4/2017CowenReiterated RatingBuy$80.00HighView Rating Details
6/28/2017William BlairInitiated CoverageMkt Perform -> Market PerformLowView Rating Details
6/28/2017WedbushReiterated RatingMarket PerformLowView Rating Details
5/24/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$47.00 -> $52.00HighView Rating Details
4/24/2017GabelliDowngradeBuy -> HoldLowView Rating Details
3/28/2017Leerink SwannSet Price TargetBuy$62.00LowView Rating Details
3/27/2017Stifel NicolausBoost Price TargetBuy -> Buy$54.00 -> $57.00LowView Rating Details
3/13/2017Goldman Sachs GroupDowngradeBuy -> Neutral$55.00MediumView Rating Details
2/7/2017Raymond James FinancialInitiated CoverageStrong-Buy$59.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Bioverativ (NASDAQ:BIVV) Earnings History and Estimates Chart

Earnings by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018        
10/26/2017Q3 2017$0.55$0.80$285.45 million$291.60 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.71$0.88$269.00 million$289.10 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Bioverativ (NASDAQ:BIVV) Earnings Estimates

2017 EPS Consensus Estimate: $2.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.59$0.59$0.59
Q2 20172$0.62$0.67$0.65
Q3 20172$0.57$0.69$0.63
Q4 20172$0.54$0.76$0.65
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bioverativ (NASDAQ:BIVV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bioverativ (NASDAQ BIVV) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 96.03%
Insider Trades by Quarter for Bioverativ (NASDAQ:BIVV)
Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2017Brian S PosnerDirectorBuy1,000$59.19$59,190.00View SEC Filing  
8/7/2017Louis J PagliaDirectorBuy2,000$59.70$119,400.00View SEC Filing  
6/28/2017Diantha DuvallInsiderSell818$60.47$49,464.46View SEC Filing  
5/30/2017Alexander J DennerDirectorBuy90,000$55.93$5,033,700.00View SEC Filing  
5/26/2017Louis J PagliaDirectorBuy2,000$57.76$115,520.00View SEC Filing  
5/24/2017Brian S PosnerDirectorBuy2,000$53.86$107,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bioverativ (NASDAQ BIVV) News Headlines

Source:
DateHeadline
ETFs with exposure to Bioverativ, Inc. : December 14, 2017ETFs with exposure to Bioverativ, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:32 PM
Bioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in CAgD PatientsBioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in CAgD Patients
www.streetinsider.com - December 12 at 5:24 PM
Bioverativ Inc. (BIVV) Reports New Data Showing Extended Prophylactic Dosing with ALPROLIX Provides Safe and ... - StreetInsider.comBioverativ Inc. (BIVV) Reports New Data Showing Extended Prophylactic Dosing with ALPROLIX Provides Safe and ... - StreetInsider.com
www.streetinsider.com - December 12 at 10:18 AM
Bioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b ... - StreetInsider.comBioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b ... - StreetInsider.com
www.streetinsider.com - December 12 at 10:18 AM
BRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patientsBRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients
www.reuters.com - December 11 at 5:11 PM
Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) PatientsBioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
finance.yahoo.com - December 11 at 5:11 PM
New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia BNew Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
finance.yahoo.com - December 11 at 10:36 AM
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint ... - Business Wire (press release)Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint ... - Business Wire (press release)
www.businesswire.com - December 10 at 5:12 PM
Study Shows Weekly Prophylactic Treatment with ELOCTATE ... - Business Wire (press release)Study Shows Weekly Prophylactic Treatment with ELOCTATE ... - Business Wire (press release)
www.businesswire.com - December 10 at 5:12 PM
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia AStudy Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A
finance.yahoo.com - December 10 at 9:48 AM
ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging StudyALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
finance.yahoo.com - December 9 at 9:53 AM
ETFs with exposure to Bioverativ, Inc. : December 4, 2017ETFs with exposure to Bioverativ, Inc. : December 4, 2017
finance.yahoo.com - December 4 at 4:59 PM
Comparing Bioverativ (BIVV) and Its RivalsComparing Bioverativ (BIVV) and Its Rivals
www.americanbankingnews.com - November 29 at 7:28 PM
BRIEF-Bioverativ says U.S. ‍FDA Has Approved Updated Labeling For AlprolixBRIEF-Bioverativ says U.S. ‍FDA Has Approved Updated Labeling For Alprolix
www.reuters.com - November 28 at 4:56 PM
Bioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIXBioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX
www.streetinsider.com - November 28 at 4:56 PM
Bioverativ is Now Oversold (BIVV) - NasdaqBioverativ is Now Oversold (BIVV) - Nasdaq
www.nasdaq.com - November 27 at 6:32 PM
Bioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX - StreetInsider.comBioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX - StreetInsider.com
www.streetinsider.com - November 27 at 6:32 PM
U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia BU.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B
finance.yahoo.com - November 27 at 6:32 PM
Bioverativ Inc (BIVV) Receives Consensus Rating of "Hold" from AnalystsBioverativ Inc (BIVV) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 7:46 AM
Bioverativ: A Rare Pearl In Biotech - Seeking AlphaBioverativ: A Rare Pearl In Biotech - Seeking Alpha
seekingalpha.com - November 25 at 3:39 PM
ETFs with exposure to Bioverativ, Inc. : November 24, 2017ETFs with exposure to Bioverativ, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 11:29 AM
Investors Buy Large Volume of Bioverativ Put Options (BIVV)Investors Buy Large Volume of Bioverativ Put Options (BIVV)
www.americanbankingnews.com - November 24 at 1:58 AM
Bioverativ IncBioverativ Inc
www.bloomberg.com - November 22 at 4:13 AM
Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceBioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 21 at 11:12 PM
Bioverativ Inc (BIVV) Given a $53.00 Price Target at Deutsche Bank AGBioverativ Inc (BIVV) Given a $53.00 Price Target at Deutsche Bank AG
www.americanbankingnews.com - November 21 at 8:15 PM
ETFs with exposure to Bioverativ, Inc. : November 13, 2017ETFs with exposure to Bioverativ, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 1:05 AM
Relative Strength Alert For BioverativRelative Strength Alert For Bioverativ
www.nasdaq.com - November 2 at 5:12 PM
ETFs with exposure to Bioverativ, Inc. : November 2, 2017ETFs with exposure to Bioverativ, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 5:12 PM
Bioverativ Inc to Post FY2017 Earnings of $2.51 Per Share, William Blair Forecasts (BIVV)Bioverativ Inc to Post FY2017 Earnings of $2.51 Per Share, William Blair Forecasts (BIVV)
www.americanbankingnews.com - November 2 at 9:28 AM
Bioverativ Inc (BIVV) Receives Average Recommendation of "Hold" from BrokeragesBioverativ Inc (BIVV) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 8:43 AM
Bioverativ Inc (BIVV) Cut to Hold at Zacks Investment ResearchBioverativ Inc (BIVV) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - November 1 at 6:28 PM
Bioverativ, Inc. :BIVV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Bioverativ, Inc. :BIVV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 1 at 5:10 PM
Bioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual MeetingBioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting
finance.yahoo.com - November 1 at 5:10 PM
Bioverativ to Present at the Credit Suisse 2017 Healthcare ConferenceBioverativ to Present at the Credit Suisse 2017 Healthcare Conference
finance.yahoo.com - November 1 at 5:10 PM
Http://www.sobi.comHttp://www.sobi.com
www.thestreet.com - October 31 at 10:41 PM
Bioverativ Inc. (BIVV) Says Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for ... - StreetInsider.comBioverativ Inc. (BIVV) Says Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for ... - StreetInsider.com
www.streetinsider.com - October 31 at 5:40 PM
Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE®Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE®
finance.yahoo.com - October 31 at 5:40 PM
Noteworthy Friday Option Activity: RGC, BIVV, MOSNoteworthy Friday Option Activity: RGC, BIVV, MOS
www.nasdaq.com - October 27 at 6:53 PM
Bioverativ Inc (BIVV) Issues  Earnings ResultsBioverativ Inc (BIVV) Issues Earnings Results
www.americanbankingnews.com - October 26 at 6:02 PM
Bioverativ Reports Third Quarter 2017 PerformanceBioverativ Reports Third Quarter 2017 Performance
finance.yahoo.com - October 26 at 4:39 PM
Biogen Spin-Off Bioverativ Shows Strong Performance And Robust Potential - Seeking AlphaBiogen Spin-Off Bioverativ Shows Strong Performance And Robust Potential - Seeking Alpha
seekingalpha.com - October 25 at 6:03 PM
Biogen Shares Hit After Poor U.S. Sales for Muscular Atrophy TreatmentBiogen Shares Hit After Poor U.S. Sales for Muscular Atrophy Treatment
www.thestreet.com - October 24 at 6:32 PM
Piper Jaffray Assumes Bioverativ Inc (BIVV) at Overweight - StreetInsider.comPiper Jaffray Assumes Bioverativ Inc (BIVV) at Overweight - StreetInsider.com
www.streetinsider.com - October 23 at 10:32 PM
ETFs with exposure to Bioverativ, Inc. : October 23, 2017ETFs with exposure to Bioverativ, Inc. : October 23, 2017
finance.yahoo.com - October 23 at 5:27 PM
Bioverativ Inc (BIVV) Stock Rating Reaffirmed by Piper Jaffray CompaniesBioverativ Inc (BIVV) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - October 23 at 9:22 AM
Bioverativ Inc (BIVV) Stock Rating Upgraded by Zacks Investment ResearchBioverativ Inc (BIVV) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 19 at 5:06 PM
Bioverativ Inc (BIVV) Forecasted to Post Q3 2017 Earnings of $0.57 Per ShareBioverativ Inc (BIVV) Forecasted to Post Q3 2017 Earnings of $0.57 Per Share
www.americanbankingnews.com - October 19 at 7:58 AM
BIOVERATIV INC (BIVV) Set to Announce Quarterly Earnings on ThursdayBIOVERATIV INC (BIVV) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - October 19 at 4:28 AM
Noteworthy Tuesday Option Activity: THC, IMDZ, BIVVNoteworthy Tuesday Option Activity: THC, IMDZ, BIVV
www.thestreet.com - October 17 at 5:23 PM
Analyzing Vical (VICL) & BIOVERATIV INC (BIVV)Analyzing Vical (VICL) & BIOVERATIV INC (BIVV)
www.americanbankingnews.com - October 15 at 6:32 PM

SEC Filings

Bioverativ (NASDAQ:BIVV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioverativ (NASDAQ:BIVV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioverativ (NASDAQ BIVV) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.